دورية أكاديمية
أعرض في EDS

Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.

التفاصيل البيبلوغرافية
العنوان: Real-World Systemic Treatment Patterns after Atezolizumab and Bevacizumab in Patients with Hepatocellular Carcinoma in the United States.
المؤلفون: Singal AG; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA., Özgürdal K; Medical Affairs Oncology, Bayer Consumer Care AG, 4052 Basel, Switzerland., Fan X; Oncology RWE, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981, USA., Vassilev Z; Oncology RWE, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981, USA., Pan X; Global Outcomes Research Department, Bayer HealthCare Pharmaceuticals Inc., Whippany, NJ 07981, USA., Multani JK; Health Economics and Outcomes Research, Real World Evidence Solutions, IQVIA US, Falls Church, VA 22042, USA., Chen CC; Health Economics and Outcomes Research, Real World Evidence Solutions, IQVIA US, Wayne, PA 19087, USA., Zhou Z; Health Economics and Outcomes Research, Real World Evidence Solutions, IQVIA US, Wayne, PA 19087, USA., He J; Advanced Analytics, IQVIA US, Plymouth Meeting, PA 19462, USA., Pisa F; Real World Evidence Oncology, Bayer AG, 13342 Berlin, Germany.
المصدر: Cancers [Cancers (Basel)] 2023 Nov 22; Vol. 15 (23). Date of Electronic Publication: 2023 Nov 22.
نوع المنشور: Journal Article
اللغة: English
بيانات الدورية: Publisher: MDPI Country of Publication: Switzerland NLM ID: 101526829 Publication Model: Electronic Cited Medium: Print ISSN: 2072-6694 (Print) Linking ISSN: 20726694 NLM ISO Abbreviation: Cancers (Basel) Subsets: PubMed not MEDLINE
أسماء مطبوعة: Original Publication: Basel, Switzerland : MDPI
مستخلص: Real-world (RW) evidence is needed to evaluate atezolizumab plus bevacizumab (atezo + bev) utilization for hepatocellular carcinoma (HCC) in clinical practice. This retrospective cohort study used administrative claims databases to evaluate treatment patterns in individuals with HCC ≥18 years of age who were initiated on atezo + bev between June 2020 and June 2022. The endpoints of this study were the proportion of individuals who discontinued atezo + bev and received subsequent systemic therapies, time to discontinuation (TTD), and time to next treatment. Overall, 825 individuals were eligible (median age 67 years; 80% male). Over a median follow-up of 15.3 months, most (72%) discontinued atezo + bev, with a median TTD of 3.5 months. A minority (19%) received subsequent therapies, with the most common second-line agents being lenvatinib (6%), cabozantinib (4%), and nivolumab (4%). The median time from index to next treatment post-atezo + bev was 5.4 months. Further research is needed to identify the patients who are most likely to benefit from atezo + bev as well as later-line HCC therapies to optimize overall survival.
References: Am J Gastroenterol. 2016 Jul;111(7):967-75. (PMID: 27166130)
J Hepatol. 2022 Apr;76(4):862-873. (PMID: 34902530)
Cancers (Basel). 2021 Oct 30;13(21):. (PMID: 34771637)
World J Gastroenterol. 2008 Jun 14;14(22):3452-60. (PMID: 18567070)
Target Oncol. 2023 Mar;18(2):221-233. (PMID: 36920648)
Ann Oncol. 2021 Jun;32(6):801-805. (PMID: 33716105)
Hepatology. 2022 Oct;76(4):1000-1012. (PMID: 35313048)
Cancer Chemother Pharmacol. 2007 Apr;59(5):561-74. (PMID: 17160391)
Gastroenterology. 2008 Feb;134(2):379. (PMID: 18242200)
J Clin Oncol. 2020 Dec 20;38(36):4317-4345. (PMID: 33197225)
Hepatol Int. 2022 Oct;16(5):1199-1207. (PMID: 35986846)
N Engl J Med. 2008 Jul 24;359(4):378-90. (PMID: 18650514)
Medicine (Baltimore). 2017 Mar;96(9):e5904. (PMID: 28248853)
J Hepatocell Carcinoma. 2016 Oct 05;3:41-53. (PMID: 27785449)
Liver Int. 2020 Aug;40(8):1800-1811. (PMID: 32432830)
Drugs Context. 2019 Apr 10;8:212577. (PMID: 31024634)
Biomark Res. 2022 Jan 9;10(1):3. (PMID: 35000616)
Cancers (Basel). 2022 Aug 15;14(16):. (PMID: 36010930)
J Hepatol. 2022 Mar;76(3):681-693. (PMID: 34801630)
Liver Cancer. 2021 Apr;10(2):107-114. (PMID: 33977087)
J Korean Med Sci. 2018 Jun 26;33(34):e213. (PMID: 30127705)
N Engl J Med. 2020 May 14;382(20):1894-1905. (PMID: 32402160)
Lancet. 2018 Mar 17;391(10125):1023-1075. (PMID: 29395269)
Hepatol Commun. 2023 Apr 26;7(5):. (PMID: 37102768)
Nat Rev Dis Primers. 2021 Jan 21;7(1):6. (PMID: 33479224)
Liver Int. 2021 Jun;41 Suppl 1:61-67. (PMID: 34155788)
Cureus. 2021 Nov 5;13(11):e19274. (PMID: 34754704)
معلومات مُعتمدة: N/A Bayer
فهرسة مساهمة: Keywords: chemotherapy; immunotherapy; liver cancer; targeted therapy; treatment patterns
تواريخ الأحداث: Date Created: 20231209 Latest Revision: 20231209
رمز التحديث: 20240829
مُعرف محوري في PubMed: PMC10705135
DOI: 10.3390/cancers15235532
PMID: 38067235
قاعدة البيانات: MEDLINE
الوصف
تدمد:2072-6694
DOI:10.3390/cancers15235532